The Duke CIVIC Vaccine Center (DCVC) hosted its annual meeting on April 27 and 28, 2022, in Durham, North Carolina. This was the first in-person annual meeting since the contract’s inception in September, 2019.
Due to the ongoing pandemic, in-person seats were limited. For those who could not travel to Durham, DCVC also hosted the meeting via Zoom as a hybrid option for virtual attendance.
We had an outstanding turnout of 106 attendees from DCVC, the Duke Manufacturing Core, the Duke Clinical Core, and NIAID. Of these, 53 were in-person at the Sheraton Imperial Hotel and Conference Center, while another 53 joined online.
Throughout the meeting, members of DCVC presented 18 scientific talks that spanned vaccine design and development, preclinical assessments, as well as assay and reagent core activities. After the meeting adjourned, members of NIAID and the DCVC Scientific Leadership Group (SLG) held a brief closed-door session to discuss next steps for the program.
NIAID attendees were then invited to tour the new Biorepository and laboratory spaces at the Duke Research and Development @RTP (RADAR) campus.